Quick Answer
Viridian Therapeutics, Inc.DE reported Operating Income Loss of -$363.40 million for the year ending 2025.
- Viridian Therapeutics, Inc.DE showed a decrease of -21.5% in Operating Income Loss from 2024 to 2025.
- This data is from Viridian Therapeutics, Inc.DE's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Viridian Therapeutics, Inc.DE's Operating Income Loss has declined by 184,364.5%.
- Historical annual values: Fiscal year 2025: -$363.40 million | Fiscal year 2024: -$299.04 million | Fiscal year 2023: -$254.45 million | Fiscal year 2022: -$134.30 million | Fiscal year 2021: -$79.73 million | Fiscal year 2020: -$110.38 million | Fiscal year 2019: -$41.98 million | Fiscal year 2018: -$33.08 million | Fiscal year 2017: -$26.53 million | Fiscal year 2016: -$16.99 million | Fiscal year 2015: -$11.19 million | Fiscal year 2014: -$6.87 million | Fiscal year 2013: -$197.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: